HOB Biotech Group Corp

HOB Biotech Group Corp EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of HOB Biotech Group Corp (688656.SS) as of Nov 13, 2026 is 123.37. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 89.00 — a change of 38.61% (higher).

EV/OCF

123.37

YoY

38.61%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of HOB Biotech Group Corp is 2025 123.37 . EV/OCF (Enterprise Value to Operating Cash Flow) of HOB Biotech Group Corp was 2024 89.00 . It decreases by 38.61% higher compared to the previous year.

The HOB Biotech Group Corp EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
192.83 CNY
Jan 1, 2019
130.88 CNY
Jan 1, 2020
154.60 CNY
Jan 1, 2021
81.99 CNY
Jan 1, 2022
150.80 CNY
Jan 1, 2023
86.70 CNY
Jan 1, 2024
89.00 CNY
Jan 1, 2025
123.37 CNY
The HOB Biotech Group Corp EV/OCF history
YEAREV/OCFYoY
123.37+38.61%
89.00+2.66%
86.70-42.50%
150.80+83.92%
81.99-46.96%
154.60+18.12%
130.88-32.12%
192.83-52.52%
406.10-71.16%
1,407.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HOB Biotech Group Corp Stock analysis

What does HOB Biotech Group Corp do? HOB Biotech Group Corp Ltd generates revenue through the research, development, production, and sale of in-vitro diagnostic reagents, primarily targeting domestic markets. The company offers allergy testing products under brands Oboke, Fubok, Shibok, and Shibok Plus, utilizing qualitative detection techniques like enzyme-linked immunosorbent assay. Self-immune testing products are sold under Norbok and Nabok, employing quantitative methods such as enzyme-linked immunoassay capture and nano-magnetic particle chemiluminescence. Additional income comes from reagent supporting testing instruments and related services. The domestic market serves as the primary customer segment for HOB Biotech's products, with healthcare providers and laboratories purchasing allergy and self-immune testing solutions. Allergy testing brands Oboke, Fubok, Shibok, and Shibok Plus cater to qualitative detection needs, while Norbok and Nabok address quantitative detection requirements for self-immune testing. The company's product portfolio is structured around these distinct brand categories and detection techniques. HOB Biotech's revenue streams are derived from the sale of branded diagnostic reagents and supporting instruments, with no mention of external partnerships or international markets. The firm focuses exclusively on domestic sales, leveraging its two product categories and five distinct brands to serve healthcare institutions requiring in-vitro diagnostic solutions. HOB Biotech Group Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HOB Biotech Group Corp stock

EV/OCF (Enterprise Value to Operating Cash Flow) of HOB Biotech Group Corp is 123.37 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of HOB Biotech Group Corp changed from 89.00 to 123.37, representing a 38.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) HOB Biotech Group Corp since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s HOB Biotech Group Corp with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — HOB Biotech Group Corp

All Key Metrics — HOB Biotech Group Corp